Showing results (801-810 of 2,122) with videos related to
Sort By:
Pageof 213
Journal of Ovarian Research|January 5, 2021
Age-related decline in the expression of GDF9 and BMP15 genes in follicle fluid and granulosa cells derived from poor ovarian respondersYan Gong, Jesse Li-Ling, Dongsheng Xiong, et al.Journal of Ovarian Research|June 12, 2021
Trophectoderm biopsy of blastocysts for a preimplantation genetic test does not affect serum β-hCG levels in early pregnancy: a study using propensity score matchingYixuan Wu, Ying Ying, Mingzhu Cao, et al.Journal of Ovarian Research|July 8, 2021
Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterusJuliane Reichenbach, Elisa Schmoeckel, Sven Mahner, et al.Journal of Ovarian Research|July 13, 2021
Integrative analysis of key candidate genes and signaling pathways in ovarian cancer by bioinformaticsCuicui Dong, Xin Tian, Fucheng He, et al.Journal of Ovarian Research|January 4, 2026
SCHEMBL4796824: a multifaceted antitumor agent targeting microtubule dynamics, DNA damage, and Wnt/β-catenin signaling in ovarian cancer cellsChaoyue Ma, XiaoFei Ding, Boze Wang, et al.Journal of Ovarian Research|October 28, 2020
Ovarian metastasis from nongynecologic primary sites: a retrospective analysis of 177 cases and 13-year experienceJing-Jing Zhang, Dong-Yan Cao, Jia-Xin Yang, et al.Journal of Ovarian Research|July 1, 2022
YY1 accelerates oral squamous cell carcinoma progression through long non-coding RNA Kcnq1ot1/microRNA-506-3p/SYPL1 axisYi Ding, Heng Duan, Jian Lin, et al.Journal of Ovarian Research|July 1, 2022
Does Anti-Müllerian hormone vary during a menstrual cycle? A systematic review and meta-analysisRasa Khodavirdilou, Marjaneh Pournaghi, Yeganeh Rastgar Rezaei, et al.Journal of Ovarian Research|May 5, 2022
A risk score system based on a six-microRNA signature predicts the overall survival of patients with ovarian cancerMin Zhou, Tao Wu, Yuan Yuan, et al.Journal of Ovarian Research|February 8, 2020
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerShoji Nagao, Ai Kogiku, Kazuhiro Suzuki, et al.Pageof 213